TIDMABC
ABCAM PLC
16 July 2019
16 July 2019
ABCAM PLC
("Abcam" or "the Company")
Abcam Enters Cell Editing Market Through
Acquisition of EdiGene's Knock-out Cell Lines and Lysates
Portfolio
- Largest off-the-shelf diploid KO library, over 2,800 cell lines
Abcam (AIM: ABC), a global innovator in life science reagents
and tools, is today pleased to announce the acquisition of the
entire live cell line and lysates portfolio of EdiGene Inc, a
leading company focused on developing genome editing technologies
into novel therapeutics for a broad range of diseases and into
creative solutions to advance drug discovery.
Using their proprietary high-throughput cell editing platform,
EdiGene developed the industry's largest off-the shelf diploid
library of over 2,800 single clonal knockout (KO) cell lines
targeting over 2,600 genes in commonly used human cancer cell lines
(including HeLa, HEK293-T, A549, HCT116, Hep G2 and MCF7).
Ready-made diploid KO cell lines are an important tool for
antibody validation. They also play a significant role in the study
and understanding of biological pathways and disease models and can
be used in screening and cellular assays. EdiGene's cell lines and
lysates are used by top academic researchers, global
biopharmaceutical companies, and leading antibody companies.
Financial terms of the transaction have not been disclosed and
are expected to have a minimal impact on revenue and earnings in
the current financial year.
Commenting on the acquisition, Cheri Walker, SVP of Corporate
Development at Abcam, said: "We are excited to be able to bring the
same level of industry-leading quality and data to the cell lines
market as we have to research antibodies. The cell line market is
in the early stages of development as a research tool, where the
provision of more choice, with the right gene targets in the right
cell lines, will allow the market to rapidly expand."
Dong Wei, CEO of EdiGene, commented: "Following our strategic
decision to focus on advancing our pipeline of biotherapeutic
products and high-throughput genome screening services, we are
pleased to be transitioning our complete cell line portfolio to the
team at Abcam. As recognised industry leaders in the provision of
biologic reagents and tools, we are confident Abcam will be able to
provide expert support to our global user-base."
The lysate range is expected to be available through the Abcam
website in early Q4 2019, with the expanded cell line offering
following throughout 2020. In addition, these products will be used
to support further knock-out antibody validation, an integral part
of Abcam's on-going antibody quality initiative.
-- ENDS -
For further information, please contact:
Abcam
+ 44 (0) 1223 696 000
Investors: James Staveley, VP Investor Relations
Media Lynne Trowbridge, VP External Relations
FTI Consulting
+44 (0) 20 3727 1000 Ben Atwell / Brett Pollard / Natalie
Garland-Collins
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to
serve life science researchers globally to achieve their mission,
faster. Providing the research and clinical communities with tools
and scientific support, the Company offers highly validated
biological binders and assays to address important targets in
critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life
sciences, Abcam's ambition is to be the most influential company in
life sciences by helping advance global understanding of biology
and causes of disease, which, in turn, will drive new treatments
and improved health. Two-thirds of the world's 750,000 life science
researchers use Abcam's affinity binders, reagents, biomarkers and
assays and the Company's products are mentioned in over 20,000 of
the 56,000 peer-reviewed papers published each year in the life
sciences.
By actively listening to and collaborating with researchers, the
Company continuously advances its portfolio to address their needs.
A transparent programme of customer reviews and datasheets,
combined with an industry-leading validation initiative, gives
researchers increased confidence in their results.
Abcam's eleven locations are in the world's leading life science
research hubs, enabling local services and multi-language support.
Founded in 1998 and headquartered in Cambridge, UK, the Company
sells to more than 130 countries. Abcam was admitted to AIM in 2005
(AIM: ABC).
To find out more, please visit www.abcam.com and
www.abcamplc.com
About EdiGene Inc
EdiGene Inc was founded in 2015, and is now headquartered in
Beijing, with operational subsidiaries in Guangzhou, China and
Cambridge, USA. EdiGene's mission is to translate cutting-edge
genome editing technologies into novel therapeutics for genetic
diseases and cancer, and into creative solutions to advance drug
discovery. EdiGene leverages proprietary platforms to develop
gene-editing therapies for a wide range of diseases, and to conduct
high-throughput genome screening to enable dissection of functional
big data in biological contexts.
More information can be found at www.EdiGene.com.
Forward looking statements
This announcement, including any information included or
incorporated by reference in this announcement, may contain
forward-looking statements (including words such as "believe",
"expect", "estimate", "intend", "anticipate" and words of similar
meaning) which are based upon current expectations and assumptions
regarding anticipated developments and other factors affecting the
Abcam Group. All statements other than statements of historical
facts may be forward-looking statements and should not be treated
as guarantees of future performance. These forward-looking
statements involve risks and uncertainties, many of which are
beyond the control of the Abcam Group, and there are important
factors that could cause actual results to differ materially from
those expressed or implied by these forward-looking statements.
These forward-looking statements speak only as at the date of this
announcement and accordingly undue reliance should not be placed on
such statements. The Abcam Group does not assume any obligation to,
and does not intend to, revise or update these forward-looking
statements, except as required pursuant to applicable law.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRABLGDRIUBBGCU
(END) Dow Jones Newswires
July 16, 2019 02:00 ET (06:00 GMT)
Abcam (LSE:ABC)
Historical Stock Chart
From Apr 2024 to May 2024
Abcam (LSE:ABC)
Historical Stock Chart
From May 2023 to May 2024